Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302

Idorsia Pharmaceuticals Ltd.

Overview

This is a Post Trial Access program for patients with Fabry Disease who previously participated in the ID-069A302 (MODIFY OLE) trial and who were still enrolled in the study at the time the Sponsor decided to discontinue ID-069A302. The program is designed to provide continued access to lucerastat.

Study Type

EXPANDED_ACCESS

Conditions

Fabry Disease

Interventions

LucerastatDRUG

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: \- Exclusion Criteria: \-

Central Contacts

Idorsia Clinical Trials Information

CONTACT

+1 856 661 37 21 idorsiaclinicaltrials@idorsia.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.